G. Migliori (Varese (VA), Italy), G. Günther (Windhoek, Namibia)
Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up S. Borisov (Moscow, Russian Federation), A. Filippov (Moscow, Russian Federation), T. Ivanushkina (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation), Y. Garmash (Moscow, Russian Federation)
|     |
Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery S. Borisov (Moscow, Russian Federation), L. D’Ambrosio (Tradate, Italy), R. Centis (Tradate, Italy), K. Dheda (Cape Town, South Africa), J. Alffenaar (Groningen, Netherlands), R. Amale (Mumbai, India), E. Belilowski (Moscow, Russian Federation), J. Bruchfeld (Stockholm, Sweden), B. Canneto (Stockholm, Sweden), J. Denholm (Melbourne, Australia), R. Duarte (Porto, Portugal), A. Esmail (Cape Town, South Africa), A. Filippov (Moscow, Russian Federation), L. Davies Forsman (Stockholm, Sweden), M. Gaga (Athens, Greece), S. Ganatra (Mumbai, India), G. Igorevna (Arkhangelsk, Russian Federation), B. Lazaro Mastrapa (Upington, South Africa), V. Manfrin (Vicenza, Italy), S. Manga (Kiev, Ukraine), A. Maryandyshev (Arkhangelsk, Russian Federation), G. Massard (Strasbourg, France), P. GonzáLez Montaner (Buenos Aires, Argentina), J. Mullerpattan (Mumbai, India), D. Palmero (Buenos Aires, Argentina), A. Pontarelli (Sondalo, Italy), A. Papavasileiou (Athens, Greece), E. Pontali (Genova, Italy), R. Romero Leyet (Springbok, South Africa), A. Spanevello (Tradate, Italy), S. Tiberi (London, United Kingdom), A. Tramontana (Victoria, Australia), Z. Udwadia (Mumbai, India), P. Viggiani (Sondalo, Italy), D. Visca (Tradate, Italy), G. Sotgiu (Sassari, Italy), G. Migliori (Tradate, Italy)
|     |
Experience of treatment Pre-XDR and XDR-TB/HIV co-infection with bedaquiline and delamanid containing regimens in Georgia N. Kiria (Tbilisi, Georgia), Z. Avaliani (Tbilisi, Georgia), N. Bolokadze (Tbilisi, Georgia), N. Kiria (Tbilisi, Georgia), L. Mikiashvili (Tbilisi, Georgia)
|     |
Long-term results of multidrug-resistant tuberculosis treatment. I. Chernokhaeva (St.-petersburg, Russian Federation), M. Pavlova (St.-petersburg, Russian Federation), A. Starshinova (St.-petersburg, Russian Federation), N. Sapozhnikova (St.-petersburg, Russian Federation), L. Archakova (St.-petersburg, Russian Federation), E. Istomina (St.-petersburg, Russian Federation), E. Ershova (St.-petersburg, Russian Federation)
|    |
DISCREPANCY ACROSS PHENOTYPIC AND GENOTYPIC RESULTS OF DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS V. Crudu (Chisinau, Republic of Moldova), S. Alexandru (Chisinau, Republic of Moldova), A. Codreanu (Chisinau, Republic of Moldova), N. Ciobanu (Chisinau, Republic of Moldova), D. Chesov (Chisinau, Republic of Moldova), V. Vilc (Chisinau, Republic of Moldova), A. Donica (Chisinau, Republic of Moldova), E. Romancenco (Chisinau, Republic of Moldova), E. Noroc (Chisinau, Republic of Moldova), N. Turcan (Chisinau, Republic of Moldova), C. Lange (Borstel, Germany)
|    |
Genotypic and phenotypic drug resistance of M.tuberculosis in patients registered in Moscow, Russia M. Krasnova (Moscow, Russian Federation), E. Belilovskiy (Moscow, Russian Federation), A. Khakhalina (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), S. Safonova (Moscow, Russian Federation), E. Nosova (Moscow, Russian Federation)
|     |
Risk factors associated with MDR-TB deaths in Romania - 6 years retrospective study R. Nedelcu (BUCHAREST, Romania), A. Socaci (TIMISOARA, Romania)
|    |
Molecular analysis of mutations in genes associated with multidrug-resistance in Mycobacterium tuberculosis isolates from patients with tuberculosis in Moscow region, Russia M. Alvarez Figueroa (Moscow, Russian Federation), R. Ludannyy (Moscow, Russian Federation), S. Popov (Moscow, Russian Federation), I. Mokrousov (St. Petersburg, Russian Federation), A. Vyazovaya (St. Petersburg, Russian Federation), G. Shipulin (Moscow, Russian Federation)
|    |
Early experience with the implementation of the WHO shorter MDR-TB treatment regimen in Singapore H. She (Singapore, Singapore), Y. Wang (Singapore, Singapore), S. Gan (Singapore, Singapore), A. Chua (Singapore, Singapore), C. Chee (Singapore, Singapore)
|     |
Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons E. Gurbanova (Tartu, Estonia), R. Mehdiyev (Baku, Azerbaijan), K. Blöndal (Reykjavik, Iceland), A. Altraja (Tartu, Estonia)
|   |
Rising trend of drug resistance among extra pulmonary TB in Northern India S. Kant (Lucknow, India), A. Maurya (Bhopal, India), V. Nag (Jodhpur, India), J. Bajpai (Lucknow, India)
|    |
The first experience of therapeutic dendritic cells vaccine administration in patients with extensively drug resistant lung tuberculosis A. Starshinova (St.-Peterburg, Russian Federation), M. Filatov (St.-Peterburg, Russian Federation), M. Nazarenko (St.-Peterburg, Russian Federation), V. Burdakov (St.-Peterburg, Russian Federation), S. Landa (St.-Peterburg, Russian Federation), E. Istomina (St.-Peterburg, Russian Federation), G. Marfina (St.-Peterburg, Russian Federation), P. Yablonskiy (St.-Peterburg, Russian Federation)
|    |
Extensively drug-resistant tuberculosis in the penitentiary facilities of the Russian Federation L. Rusakova (Moscow, Russian Federation), S. Sterlikov (Moscow, Russian Federation), S. Ponomarev (Moscow, Russian Federation)
|     |
Knowledge and attitudes of chest physicians regarding screening of household contacts of MDR TB patients & infection control. Z. Udwadia (Mumbai, India), S. Ganatra (Mumbai, India), H. Poonawala (Chennai, India), G. Kishore (Mumbai, India), J. Mullerpattan (Mumbai, India)
|     |
Metabolism of connective tissue in multidrug-resistant pulmonary tuberculosis I. Ovcharenko (Kharkiv, Ukraine), O. Shevchenko (Kharkiv, Ukraine), O. Pogorelova (Kharkiv, Ukraine), S. Ovcharenko (Kharkiv, Ukraine)
|     |
Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance D. Falzon (Geneva, Switzerland), N. Ford (Geneva, Switzerland), E. Jaramillo (Geneva, Switzerland), P. Nahid (San Francisco, United States of America), P. Cegielski (Atlanta, United States of America), H. Schunemann (Hamilton, Canada), J. Brozek (Hamilton, Canada), K. Weyer (Geneva, Switzerland)
|    |
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis C. Chung (Daejeon, Republic of Korea), J. Kim (Daejeon, Republic of Korea), S. Jung (Daejeon, Republic of Korea), J. Lim (Daejeon, Republic of Korea), K. Lee (Cheongju, Republic of Korea), K. Shin (Cheongju, Republic of Korea), J. Park (Cheongju, Republic of Korea), J. Min (Daejeon, Republic of Korea)
|    |